Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatoid Arthritis Drugs May Cut Cardiovascular Risk

Kathleen Louden  |  Issue: April 2012  |  April 6, 2012

The researchers found that, when analyzing their entire scleroderma population, each 1-mm Hg increase in RV systolic pressure per year was strongly associated with an increased risk of PAH development and death (P<.0001 each).

“These data are supportive of the current recommendation for performing annual echocardiography in a scleroderma population,” Dr. Shah said. She added that a prospective study is needed to define the optimal screening strategy.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Knee Arthritis

The idea behind the IDEA, or Intensive Diet and Exercise for Arthritis, Trial was to determine if weight loss in older, overweight adults with painful knee osteoarthritis reduces pain and improves function and mobility (abstract 722). This international, prospective, single-blind, randomized controlled trial enrolled 454 patients aged 55 years or older who had a sedentary lifestyle and were overweight or obese.

According to lead author Stephen P. Messier, PhD, professor and director of the J. B. Snow Biomechanics Laboratory at Wake Forest University, patients were randomly assigned to one of three interventions for 18 months. Treatment arms were as follows:

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Diet only: An energy-intake deficit of 800 to 1,000 kcal.d-1; patients ate up to two meal replacements daily.
  2. Diet and exercise: Besides the same diet as in the first treatment arm, patients exercised by walking or doing weight training for an hour three days a week.
  3. Exercise-only (control): These patients exercised without dieting.

The goal of both diet groups was to lose at least 10% of their body weight. Participants met in groups, and Dr. Messier said such support contributed to the high retention rate (88%).

Gerd R. Burmester, MD

It’s quite remarkable that even if the patients had failed two or more TNF-inhibiting agents, they still had a significantly increased response to tofacitinib.

—Gerd R. Burmester, MD

“At 18 months, all groups showed improved mobility, pain, and function, but diet and exercise was superior in virtually all measures,” Dr. Messier said.

An intent-to-treat analysis found that the diet–exercise group had about a 50% decrease in pain on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and 47% improvement in the WOMAC physical function score. These improvements were significantly better than in the other groups (P<.001 and P<.005, respectively). Participants who both dieted and exercised lost 11.4% of their body weight (mean of 10.6 kg).

Compared with the other groups, the diet–exercise group significantly quickened their walking speed (12% faster; P=.005). “It was faster than healthy, middle-aged women,” Dr. Messier said.

Two audience members called the results “very impressive.”

Juvenile Idiopathic Arthritis

A trial of aggressive multidrug treatment within a year after diagnosis of polyarticular juvenile idiopathic arthritis (JIA) failed to meet its primary endpoint of inducing clinically inactive disease in six months (abstract 721).

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone DisordersRheumatoid ArthritisSystemic Sclerosis Tagged with:ACR/ARHP Annual MeetingcardiovasculardrugJuvenile idiopathic arthritisMethotrexateOsteoarthritisPainpatient careRheumatoid arthritisrheumatologistSclerodermaTofacitinibTreatment

Related Articles
    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    February 16, 2021

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

    Diet May Help Reduce Inflammation in RA

    March 27, 2023

    In a small study, an anti-inflammatory diet helped reduce pain and swelling in a subset of people with rheumatoid arthritis (RA). Diet changes are complementary to standard treatment. Diet-related research can be challenging, but many patients with RA are motivated to try healthy changes.

    Tofacitinib with Methotrexate Not Inferior to Adalimumab with Methotrexate

    July 13, 2017

    Highlights from the 2017 EULAR Congress MADRID—Tofacitinib (a JAK inhibitor) used with methotrexate (MTX) is not inferior to adalimumab (a TNF inhibitor) plus MTX in rheumatoid arthritis (RA) patients who’ve had an inadequate response to MTX alone, according to results of a Phase 3B/4 trial presented in a session at the Annual European Congress of…

    What Diet to Recommend to Patients with Rheumatoid Arthritis?

    November 1, 2013

    With no clear-cut, evidence-based dietary guidelines for RA, rheumatologists should advocate for a balanced diet to help patients reduce their risk of obesity, cardiovascular disease, and osteoporosis

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences